

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM586754

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Manchester Securities Corp.		01/21/2020	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	CorMedix Inc.		
Street Address:	400 CONNELL DRIVE, SUITE 5000		
City:	BERKELEY HEIGHTS		
State/Country:	NEW JERSEY		
Postal Code:	07922		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Serial Number:	85304993	NEUTROLIN	
Serial Number:	78085378	NEUTROLIN	
Serial Number:	85153809	GEL LOCK	
CORRESPONDENCE DATA			
Fax Number:	2027393001		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	202.739.5965		
Email:	joseph.washington@morganlewis.com, antonio.teixeira@morganlewis.com		
Correspondent Name:	Joseph E. Washington		
Address Line 1:	1111 Pennsylvania Avenue, NW		
Address Line 2:	Attention: TMSU		
Address Line 4:	Washington, D.C. 20004-2541		
NAME OF SUBMITTER:	Joseph E. Washington		
SIGNATURE:	/Joseph E. Washington/		
DATE SIGNED:	07/15/2020		
Total Attachments: 19			
source=103164_Manchester_Release#page1.tif			
source=103164_Manchester_Release#page2.tif			

CH \$90.00 85304993

source=103164_Manchester_Release#page3.tif
source=103164_Manchester_Release#page4.tif
source=103164_Manchester_Release#page5.tif
source=103164_Manchester_Release#page6.tif
source=103164_Manchester_Release#page7.tif
source=103164_Manchester_Release#page8.tif
source=103164_Manchester_Release#page9.tif
source=103164_Manchester_Release#page10.tif
source=103164_Manchester_Release#page11.tif
source=103164_Manchester_Release#page12.tif
source=103164_Manchester_Release#page13.tif
source=103164_Manchester_Release#page14.tif
source=103164_Manchester_Release#page15.tif
source=103164_Manchester_Release#page16.tif
source=103164_Manchester_Release#page17.tif
source=103164_Manchester_Release#page18.tif
source=103164_Manchester_Release#page19.tif

RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

This **RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST** (“**Release**”) is made and effective as of October 23, 2013 and granted by Manchester Securities Corp., a Delaware corporation, and Kingsbrook Opportunities Master Fund LP (by Kingsbrook Opportunities GP LLC, its general partner), as Secured Parties (collectively the “**Secured Parties**”), in favor of CorMedix Inc., a Delaware corporation (the “**Company**”), and CorMedix Europe GmbH, its subsidiary (each a “**Grantor**” and collectively, the “**Grantors**”) and their successors, assigns and legal representatives. Capitalized terms used and not otherwise defined in this Release shall have the meanings assigned to them in the Security Agreement (defined below).

WHEREAS, pursuant to that certain Security Agreement, dated as of May 30, 2013 (the “**Security Agreement**”), among the Grantors, the Secured Parties and the other holders of the Company’s Senior Secured Convertible Notes (the “**Notes**”) party thereto, each Grantor pledged and granted to the Secured Parties a security interest in and to all of the right, title and interest of such Grantor in, to and under the IP Collateral (as defined below); and

WHEREAS, the Notes have been repaid in full and the Grantors have requested that the Secured Parties enter into this Release in order to effectuate, evidence and record the release and reassignment to the Grantors of any and all right, title and interest the Agent the Secured Parties may have in the IP Collateral pursuant to the Security Agreement.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Secured Parties hereby state as follows:

1. **Release of Security Interest.** The Secured Parties, on behalf of themselves and successors, legal representatives and assigns, hereby terminate the Security Agreement and terminate, release and discharge any and all security interests that they have pursuant to the Security Agreement in any and all right, title and interest of the Grantors, and reassigns to the Grantors any and all right, title and interest that it may have, in, to and under the following (collectively, the “**IP Collateral**”):

(a) the United States, international, and foreign patents, patent applications and patent licenses set forth in Exhibit A hereto, together with all reissues, divisions, continuations, continuations-in-part, extensions and reexaminations thereof, and all rights therein provided by international treaties or conventions (the “**Patents**”);

(b) the United States and foreign trademark and service mark registrations, applications, and licenses set forth in Exhibit B hereto (the “**Trademarks**”);

(c) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse, or breach with respect to the Patents or Trademarks, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

(e) any and all Proceeds of the foregoing, for income, royalties, and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the foregoing or arising from any of the foregoing.

2. **Entire Agreement**. This Release represents the final agreement among the parties and may not be contradicted by evidence of prior, contemporaneous or subsequent oral agreements of the parties or by prior or contemporaneous written agreements.

3. **Governing Law**. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

[Signature Page Follows]

IN WITNESS WHEREOF, the Secured Parties have caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

MANCHESTER SECURITIES CORP.

By: [Signature]
Name: Elliot Greenberg
Title: Vice President

Address for Notices: 40 West 57th Street
New York, NY 10019

KINGSBROOK OPPORTUNITIES MASTER
FUND LP, by KINGSBROOK OPPORTUNITIES
GP LLC, its general partner.

By: _____
Name:
Title:

Address for Notices:

ACKNOWLEDGMENT


STATE OF NEW YORK)
COUNTY OF NEW YORK)SS.
)

On the 21st day of January, 2020 before me personally appeared Elliot Greenberg, personally known to me to be the person whose name is subscribed to the foregoing instrument, who, being duly sworn, did depose and say that such individual executed the same in such individual's authorized capacity as the Vice President of Manchester Securities Corp., the corporation described, and acknowledged the instrument to be the free act and deed of Manchester Securities Corp. for the uses and purposes mentioned in the instrument.

My Commission Expires:
December 05, 2021

[Signature]
Notary Public

Printed Name: Oksana Bitetti
OKSANA BITETTI
Notary Public, State of New York
No. 01B16137693 Qualified in Kings County
Certificate Filed in New York County
Commission Expires December 05, 2021



ACKNOWLEDGMENT

STATE OF NEW YORK)
COUNTY OF NEW YORK)SS.
)

On the _____ day of _____, 2020 before me personally appeared _____, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the foregoing instrument, who, being duly sworn, did depose and say that such individual executed the same in such individual's authorized capacity as the _____ of Kingsbrook Opportunities GP LLC., the corporation described, and acknowledged the instrument to be the free act and deed of Kingsbrook Opportunities GP LLC for the uses and purposes mentioned in the instrument.

My Commission Expires:
_____, 20_____

Notary Public
Printed Name:

Exhibit A

**Cormedix Inc.
Patent Status Report**

Docket No.	Title	Status	Filing Date Serial No.	Patent Date Patent No.	Remarks
CORMEDIX- 90018.0.1 EUROPEAN (F222903)	HEMODIALYSIS ACCESS APPARATUS	European patent application abandoned	05/20/99 99924398.3		European national phase of PCT/US99/1118 3
CORMEDIX- 90018.0.3	ANTIMICROBIAL LOCKS COMPRISING TAURINAMIDE DERIVATIVES AND CARBOXYLIC ACIDS AND/OR SALTS THEREOF	Patent issued	05/10/99 09/307,916	12/26/00 6,166,007	
CORMEDIX- 90018.0.3 PCT (F223022)	TAUROLIDINE/ACID COMPOSITION FOR USE AS AN ANTIBIOTIC LOCK	International (PCT) patent application moved national (see below)	05/28/99 PCT/US99/1191 7		

CORMEDIX-90018.0.3 EUROPEAN (F223003)	ANTIMICROBIAL COMPOSITIONS COMPRISING TAUROLIDINE, CITRIC ACID AND SODIUM CITRATE	European patent issued	05/28/99 9959111.8	05/03/06 1089738	European national phase of PCT/US99/11917 File 1 and File 2 Validated in Germany, Belgium, Switzerland, Spain, France, UK, Ireland, Italy, Netherlands and Sweden Renewal fees due 05/28/13
CORMEDIX-90018.0.6	BIOCIDAL LOCKS	Patent issued	01/18/00 09/483,966	02/26/02 6,350,251	File not received (contacted Sughrue and made a file)
CORMEDIX-90018.0.6 JAPAN (F223104)	BIOCIDAL LOCKS	Japanese patent issued	05/08/01 2001-137623	11/30/12 5143982	
CORMEDIX-90018.0.6 JAPAN DIV(F223104)	BIOCIDAL LOCKS	Japanese patent application pending	05/08/01 2011-147588		
CORMEDIX-90018.0.7	METHOD AND APPARATUS FOR OVERCOMING INFECTION IN A TISSUE POCKET SURROUNDING AN IMPLANTED DEVICE	Patent issued	08/16/00 09/640,292	09/17/02 6,451,003	3 rd maintenance fee due 03/17/14

CORMEDIX-90018.0.7 CHINA (F223216)	APPARATUS FOR OVERCOMING INFECTION IN A TISSUE POCKET SURROUNDING AN IMPLANTED DEVICE	Chinese patent issued	04/01/02 02108777.6	11/05/08 ZL02108777.6	
CORMEDIX-90018.0.7 CHINA DIV (CORMEDIX-F-223216-1 CHINA DIV)	METHOD AND APPARATUS FOR OVERCOMING INFECTION IN A TISSUE POCKET SURROUNDING AN IMPLANTED DEVICE	Chinese patent issued	04/01/02 200810213381.6	06/27/12 ZL200810213381.6	
CORMEDIX-90018.0.7 HONG KONG (F223239)	METHOD AND APPARATUS FOR OVERCOMING INFECTION IN A TISSUE POCKET SURROUNDING AN IMPLANTED DEVICE	Hong Kong patent issued	04/28/09 04102592.4	07/10/09 HK1059746	
CORMEDIX-90018.0.7 HONG KONG DIV (CORMEDIX-F-223239-1 HONG KONG DIV)	METHOD AND APPARATUS FOR OVERCOMING INFECTION IN A TISSUE POCKET SURROUNDING AN IMPLANTED DEVICE	Hong Kong patent application pending	10/14/09 09109478.3		

CORMEDIX-90018.0.8	COATINGS AND SOAKS FOR MEDICAL PROSTHETIC DEVICES COMPRISING TAURINAMIDE DERIVATIVES AND CARBOXYLIC ACIDS AND/OR SALTS THEREOF	Patent issued	04/19/00 09/552,198	05/27/03 6,569,852	DIV of 09/307,916 3 rd maintenance fee due 11/27/14
CORMEDIX-90018.0.13	ANTIMICROBIAL LOCKS COMPRISING TAURINAMIDE DERIVATIVES AND CARBOXYLIC ACIDS AND/OR SALTS THEREOF	Patent issued	12/29/00 09/741,321	07/23/02 6,423,706	CIP of 09/307,916 3 rd maintenance fee due 01/23/14
CORMEDIX-90018.0.13 CHINA (P223516)	ANTIMICROBIAL LOCKS COMPRISING TAURINAMIDE DERIVATIVES AND CARBOXYLIC ACIDS AND/OR SALTS THEREOF	Chinese patent issued	04/01/02 02108774.1	02/21/07 ZL02108774.1	
CORMEDIX-90018.0.13 HONG KONG (P223539)	ANTIMICROBIAL LOCKS COMPRISING TAURINAMIDE DERIVATIVES AND CARBOXYLIC ACIDS AND/OR SALTS THEREOF	Hong Kong patent issued	08/20/07 04102588.0	10/12/07 HK1059535	

CORMEDIX-90018.0.15	PERITONEAL DIALYSIS SOLUTION WITH TAUROLIDINE	Patent issued	05/31/02 10/160,529	10/12/04 6,803,363	3 rd maintenance fee due 04/12/16
CORMEDIX-90018.0.15 PCT (F223322)	PERITONEAL DIALYSIS SOLUTION WITH TAUROLIDINE	International (PCT) patent application moved national (see below)	05/29/03 PCT/US03/17006		
CORMEDIX-90018.0.15 PCT CHINA (F223316)	PERITONEAL DIALYSIS SOLUTION WITH TAUROLIDINE	Chinese patent application abandoned	05/29/03 03812453.6		Chinese national phase of PCT/US03/17006
CORMEDIX-90018.0.15 PCT EUROPEAN (F223303)	PERITONEAL DIALYSIS SOLUTION WITH TAUROLIDINE	European patent issued	05/29/03 03736756.2	02/22/12 1509231	European national phase of PCT/US03/17006 Validated in Austria, Belgium, Bulgaria, Switzerland, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, Great Britain, Greece, Hungary, Italy, Luxembourg, Monaco, the Netherlands, Portugal, Romania, Sweden, Slovenia, Slovakia, Turkey and Ireland Renewal fees due 05/29/13

CORMEDIX-90018.0.15 PCT HONG KONG	PERITONEAL DIALYSIS SOLUTION WITH TAUROLIDINE	Hong Kong patent application abandoned	06102064.1		File not received (contacted Sughrue and made a file)
CORMEDIX-90018.0.15 PCT JAPAN (F223304)	PERITONEAL DIALYSIS SOLUTION WITH TAUROLIDINE	Japanese patent issued	05/29/03 2004-508814	12/02/11 4874543	Japanese national phase of PCT/US03/17006 Renewal fee due 12/02/14
CORMEDIX-90018.0.16	METHOD AND APPARATUS FOR OVERCOMING INFECTION IN A TISSUE POCKET SURROUNDING AN IMPLANTED DEVICE	Patent issued	05/08/02 10/140,630	06/10/03 6,575,945	DIV of 09/640,292 3 rd maintenance fee due 12/10/14
CORMEDIX-1 (90018.0.17)	ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN	Patent issued	11/02/04 10/979,547	04/13/10 7,696,182	1 st maintenance fee due 10/13/13 2 nd maintenance fee due 10/13/17 3 rd maintenance fee due 10/13/21

<p>90018.0.17/CO RMEDEX-1 CON</p>	<p>ANTIMICROBI AL LOCKING SOLUTIONS COMPRISING TAURINAMID E DERIVATIVES AND BIOLOGICAL LY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRA TIONS OF HEPARIN</p>	<p>Non-provisional patent application abandoned</p>	<p>03/11/10 12/561,183</p>		
<p>90018.0.17/CO RMEDEX-1 CON 2</p>	<p>ANTIMICROBI AL LOCKING SOLUTIONS COMPRISING TAURINAMID E DERIVATIVES AND BIOLOGICAL LY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRA TIONS OF HEPARIN</p>	<p>Non-provisional patent application pending</p>	<p>09/02/11 13/199,605</p>		

<p>CORMEDIX-90018.0.17 PCT (F223422)</p>	<p>ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN</p>	<p>International (PCT) patent application moved national (see below)</p>	<p>10/12/05 PCT/US05/3645 1</p>		
<p>CORMEDIX-90018.0.17 PCT CHINA (F223416)</p>	<p>ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN</p>	<p>Chinese patent application pending</p>	<p>10/12/05 200580045701. 6</p>		<p>Chinese national phase application of PCT/US05/3645 1</p>

<p>CORMEDIX-90018.0.17 PCT CHINA DIV (F223416)</p>	<p>ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN</p>	<p>Chinese patent application pending</p>	<p>10/12/05 201210513004.0</p>		
<p>CORMEDIX-90018.0.17 PCT EUROPEAN (F223403)</p>	<p>ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN</p>	<p>European patent application pending</p>	<p>10/12/05 05803391.1</p>		<p>European national phase application of PCT/US05/3645</p>

<p>CORMEDIX-90018.0.17 PCT HONG KONG (F223439)</p>	<p>ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN</p>	<p>Hong Kong patent application pending</p>	<p>05/07/08 08105100.8</p>		
<p>CORMEDIX-90018.0.17 PCT JAPAN (F223404)</p>	<p>ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN</p>	<p>Japanese patent application abandoned</p>	<p>10/12/05 2007-540313</p>		<p>Japanese national phase application of PCT/US05/36451</p>

CORMEDIX-90018.0.17 PCT JAPAN DIV (F223404)	ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN	Japanese patent application pending	10/12/05 2012-279870		
POLA-01	PREVENTION OF INDWELLING DEVICE RELATED INFECTION: COMPOSITION AND METHODS	Non-provisional patent application abandoned	02/02/04 10/769,961		
POLA-01 CON	PREVENTION OF INDWELLING DEVICE RELATED INFECTION: COMPOSITION AND METHODS	Non-provisional patent application pending	07/23/12 13/555,955		
POLA-01 DIV I	PREVENTION OF INDWELLING DEVICE RELATED INFECTION: COMPOSITION AND METHODS	Non-provisional patent application abandoned	07/24/09 12/460,787		

POLA-01 DIV I CON	PREVENTION OF INDWELLING DEVICE RELATED INFECTION; COMPOSITIO N AND METHODS	Non-provisional patent application pending	08/09/12 13/571,107		
POLA-01 DIV II	PREVENTION OF INDWELLING DEVICE RELATED INFECTION; COMPOSITIO N AND METHODS	Non-provisional patent application abandoned	07/24/09 12/460,786		
POLA-01 DIV II CON	PREVENTION OF INDWELLING DEVICE RELATED INFECTION; COMPOSITIO N AND METHODS	Non-provisional patent application pending	08/09/12 13/570,786		
POLA-02 PROV (POLA-2 PROV)	TAUROLIDIN E FORMULATIO NS AND DELIVERY; THERAPEUTI C TREATMENTS AND ANTIMICROBI AL PROTECTION AGAINST BACTERIAL BIOFILM FORMATION	Provisional patent application abandoned in favor of International (PCT) application (see below)	05/14/04 60/571,272		

POLA-02 PCT	TAUROLIDIN E FORMULATIO NS AND DELIVERY: THERAPEUTI C TREATMENTS AND ANTIMICROBI AL PROTECTION AGAINST BACTERIAL BIOFILM FORMATION	International (PCT) patent application moved national (see below)	05/16/05 PCT/EP2005/00 5438		
POLA-02 PCT JAPAN	TAUROLIDIN E FORMULATIO NS AND DELIVERY: THERAPEUTI C TREATMENTS AND ANTIMICROBI AL PROTECTION AGAINST BACTERIAL BIOFILM FORMATION	Japanese patent application pending	05/16/05 2007-512125		
POLA-02 PCT JAPAN DIV	TAUROLIDIN E FORMULATIO NS AND DELIVERY	Japanese patent application pending	05/16/05 2012-004150		

POLA-02 PCT UNITED STATES	TAUROLIDIN E FORMULATIO NS AND DELIVERY: THERAPEUTI C TREATMENTS AND ANTIMICROBI AL PROTECTION AGAINST BACTERIAL BIOFILM FORMATION	Non-provisional patent application abandoned	11/14/06 11/596,525		
POLA-02 CON	TAUROLIDIN E FORMULATIO NS AND DELIVERY: THERAPEUTI C TREATMENTS AND ANTIMICROBI AL PROTECTION AGAINST BACTERIAL BIOFILM FORMATION	Non-provisional patent ap pending	04/26/12 13/437,091		

Exhibit B

**Cormedix Inc.
Trademark Status Report**

Docket No.	Mark	Status	Filing Date Serial No.	Registrat. Date Registrat. No.	Remarks
CORMEDIX/T M-1 EUROPEAN	CLS	European trademark registered	10/15/99 001347509	11/20/00 001347509	Renewal due 10/3
CORMEDIX/T M-1 JAPAN	CLS	Japanese trademark registered	10/18/99 H11-094628	03/02/01 4456241	Renewal due 03/02/21
CORMEDIX/T M-2	NEUTROLIN	Trademark expired	09/25/01 78/085,378	04/26/05 2,944,728	
CORMEDIX/T M-2A	NEUTROLIN	Trademark application pending - application allowed, mark published for opposition, Notice Of Allowance issued, Statement Of Use now due in case	04/26/11 85/304,993		Statement of Use due 11/08/13
CORMEDIX/T M-2 CHINA	NEUTROLIN	Chinese trademark registered	05/03/11 9414482	05/21/12 9414482	Renewal due 05/20/22
CORMEDIX/T M-2 EUROPEAN	NEUTROLIN	European trademark registered	11/07/01 002442168	04/24/03 002442168	Renewal due 11/07/21
CORMEDIX/T M-2 JAPAN	NEUTROLIN	Japanese trademark registered	02/04/11 7297/2011	08/11/11 5431673	Renewal due 08/12/21
CORMEDIX/T M-3	GEL LOCK	Trademark application abandoned	10/15/10 85/133,809		